Home
Contact us
Site map
Québec.ca
FAQ
Français
Advanced search
Consolidated Statutes and Regulations
Consolidated Statutes
Consolidated Regulations
Annual Statutes and Regulations
Annual Statutes
Annual Regulations
Additional information
Québec Official Publisher
What’s new?
Information note
Policy of the Minister of Justice
Laws: Amendments
Laws: Provisions not in force
Laws: Provisions brought into force
Annual Statutes: PDF versions since 1996
Regulations: Amendments
Annual Regulations: PDF versions since 1996
Court Decisions
p-12, r. 6
- Regulation respecting the medications that a podiatrist who obtained a permit to practise before 1976 may administer or prescribe
Table of contents
Occurrences
0
Current Version
Full text
Updated to 1 September 2012
This document has official status.
chapter
P-12, r. 6
Regulation respecting the medications that a podiatrist may use in the practice of his profession or administer or prescribe to his patients
PODIATRISTS — MEDICATIONS
Podiatry Act
(chapter P-12, s. 12)
.
P-12
09
September
01
1
2012
1
.
A podiatrist entered on the roll of the Ordre des podiatres du Québec may use in the practice of his profession or administer or prescribe to his patients the medications listed in Schedule I or in Schedule II, subject to the conditions prescribed in this Regulation.
A podiatrist who administers or prescribes to patients the medications listed in Schedule II that are not medications listed in Schedule I must hold a certificate issued by the Ordre des podiatres du Québec acknowledging that the podiatrist received university training in podiatric medicine in the last 5 years, comprising a minimum of 1145 hours apportioned as follows:
(
1
)
540 hours in anatomy-physiology;
(
2
)
90 hours in biochemistry;
(
3
)
105 hours in microbiology;
(
4
)
275 hours in general pathologies;
(
5
)
90 hours in basic pharmacology; and
(
6
)
45 hours in clinical pharmacology.
A podiatrist whose training referred to in subparagraphs 1 to 6 of the second paragraph was received more than 5 years previously must successfully complete the continuing education activities determined by the Ordre des podiatres du Québec pursuant to paragraph
o
of section 94 of the Professional Code (chapter C-26) and hold a certificate issued by the Order acknowledging that the activities were successfully completed, before the medications listed in Schedule II that are not medications listed in Schedule I may be administered to patients.
O.C. 1057-91, s. 1
;
O.C. 142-2003, s. 1
.
2
.
(Revoked).
O.C. 1057-91, s. 2
;
O.C. 142-2003, s. 2
.
3
.
(Omitted).
O.C. 1057-91, s. 3
.
SCHEDULE I
NOTE : Medications without specification are intended for topical application.
________________________________________________________________
Substances Specification
________________________________________________________________
Acetaminophen Pharmaceutical forms intended
for oral and rectal
administration
Acetic, glacial acid
Acetylsalicylic, Pharmaceutical forms intended
for oral administration
Aluminium and its salts
Almond, sweet oil
Amino acids
Amcinonide Quantity limited for 30 days
Anthralin (dithranol)
Silver nitrate
Silver sulfadiazine
Colloidal oatmeal
Bacitracin and its salts
Beclomethasone and its salts
Benzalkonium
Benzocaine
Betamethasone benzoate
Betamethasone Quantity limited for 30 days
dipropionate
Betamethasone valerate
Bupivacaine and Pharmaceutical forms intended
its salts for administration by injection
for local use only
Calcipotriol
Calcium acetate
Camphor
Cantharin
Capsaicin
Cetrimide
Cetirizine Pharmaceutical form intended
hydrochloride for oral administration
Chlorhexidine and its salts
Chlorphenesin
Chlorprocaine Pharmaceutical form intended
hydrochloride for administration by injection
for local use only
Ciclopirox olamine
Cinchocaine
Clioquinol
(iodochlorhydroxyquin)
Clobetasol Quantity limited for 30 days
proprionate
Clobetasone butyrate
Clotrimazole
Collagenase
Dakin’s solution
Desonide
Desoximetasone Quantity limited for 30 days
Deoxyribonuclease
Dichloracetic acid
Diflucortolone Quantity limited for 30 days
valerate
Diphenhydramine Pharmaceutical forms intended
for oral and topical
administration
Econazole nitrate
Epinephrine Pharmaceutical forms for the
(adrenaline) emergency treatment of
anaphylactic reactions in
the form of self-injector or
vial
Pharmaceutical form associated
with local anaesthetics
Erythromycin
Ethyl chloride
Fibrinolysin
Flumetasone pivalate
Fluocinolone Quantity limited for 30 days
acetonide
Fluocinode Quantity limited for 30 days
Formalin
Framycetin sulfate
Fusidic acid
Gentamicin sulfate
Gentian, violet
Mineral and vegetal tar
Gramicidin
Halcinodide Quantity limited for 30 days
Hexachlorophene
Mineral oil
Hydrocortisone and its salts
Hydroxyzine Pharmaceutical form intended
hydrochloride for oral administration
Povidone iodine
Iodine tincture
Isopropyl myristate
Ketoconazole
Lactic acid
Lanolin
Lidocaine and Pharmaceutical forms intended
its salts for topical application and
administration by injection
for local use only
Loratadine Pharmaceutical form intended
for oral administration
Lorazepam Pharmaceutical form intended
for oral and sublingual
administration in anticipation
of surgical procedures,
containing 0.5 mg or 1 mg
of Lorazepam per tablet
Quantity limited to 4 tablets
Mafenide and its salts
Menthol
Mepivacaine Pharmaceutical form intended
for administration by injection
for local use only
Methylpolysiloxanes
Methylprednisolone acetate
Miconazole nitrate
Mometasone furorate
Mupirocin
Neomycin sulfate
Nystatin
Oxiconazole
Phenol
Podophyllin
Polymyxin B sulfate
Pramoxine
Prilocaine Pharmaceutical forms intended
for topical application and
administration by injection
for local use only
Procaine Pharmaceutical form intended
for administration by injection
for local use only
Resorcinol and its salts
Diethylamine salicylate
Magnesium salicylate
Methyl salicylate
Triethanolamine salicylate
Salicylic acid
Synthetic sebum
Silicone
Sodium thiosulfate
Sulphur, colloidal,
precipitate or sublimate
Tazarotene
Terbinafine
Tetracaine and Pharmaceutical forms intended
its salts for topical application and
administration by injection
for local use only
Tioconazole
Tolnaftate
Triamcinolone Quantity limited for 30 days
acetonide
Trichloroacetic acid
Urea Pharmaceutical form intended
for topical application, with
a concentration of 30% or less
White petroleum jelly
Zinc oxide
O.C. 1057-91, Sch. I
;
O.C. 142-2003, s. 3
;
O.C. 522-2005, s. 1
.
SCHEDULE II
NOTE : Medications without specification are intended for topical application.
________________________________________________________________
Substances Specification
________________________________________________________________
Acetaminophen Pharmaceutical form intended
for oral and rectal administration
Acetaminophen and Pharmaceutical form intended
codeine for oral administration
(in combination) containing 30 mg or less of
codeine per tablet
Acetic, Quantity limited to 24 tablets/
glacial acid 72 hours
Acetylsalicyclic Pharmaceutical form intended
acid for oral administration
Aluminium and its salts
Almond, sweet oil
Amcinonide Quantity limited for 30 days
Amino acids
Anthralin (dithranol)
Silver nitrate
Silver sulfadiazine
Colloidal oatmeal
Bacitracin and its salts
Beclomethasone and its salts
Benzalkonium
Benzocaine
Betamethasone Pharmaceutical forms
acetate and intended for administration by
phosphate intramuscular or intradermal
injection
Betamethasone benzoate
Betamethasone Quantity limited for 30 days
dipropionate
Betamethasone valerate
Bleomycin sulfate Pharmaceutical form injectable in
the plantar lesion without
exceeding 0.8 units up to a maximum
of 5 units per treatment
Bupivacaine and Pharmaceutical form intended for
its salts administration by injection for
local use only
Calcipotriol
Calcium acetate
Camphor
Cantharin
Capsaicin
Celecoxib Pharmaceutical form intended for
oral administration
Quantity limited for 30 days
Cetirizine Pharmaceutical form intended for
hydrochloride oral administration
Cetrimid
Chlorhexidine and its salts
Chlorphenesin
Chlorprocaine Pharmaceutical form intended for
hydrochloride administration by injection for
local use only
Ciclopirox olamine
Cinchocaine
Clioquinor
(iodochlorhydroxyquin)
Clobetasol Quantity limited for 30 days
proprionate
Clobetasone butyrate
Clotrimazole
Collagenase
Dakin’s solution
Desonide
Desoximetasone Quantity limited for 30 days
Deoxyribonuclease
Dichloracetic acid
Diclofenac, Pharmaceutical form intended
potassic and sodic for oral administration
Quantity limited for 30 days
Diflucortolone Quantity limited for 30 days
valerate
Dyphenhydramine Pharmaceutical forms intended
for oral administration and
administration by intramuscular,
subcutaneous or intradermal
injection
Econazole nitrate
Epinephrine Pharmaceutical forms for the
(adrenaline) emergency treatment of
anaphylactic reactions in the
form of auto-injector or vial
Pharmaceutical form associated
with local anaesthetics
Erythromycin
Ethyl chloride
Fibrinolysin
Flumetasone pivalate
Fluocinolone Quantity limited for 30 days
acetonide
Fluocinode Quantity limited for 30 days
5-fluorouracil 0.1% pharmaceutical form intended
for topical application in the
case of plantar warts resistant to
first-line treatments
Formaline
Framycetin sulfate
Fusidic acid
Gentamicin sulfate
Gentian, violet
Mineral and vegetal tar
Gramicidin
Halcinodide Quantity limited for 30 days
Hexachlorophene
Mineral oil
Hydrocortisone and its salts
Hydroxyzine Pharmaceutical form intended for
hydrochloride oral administration
Ibuprofen Pharmaceutical form intended for
oral administration
Quantity limited for 30 days
Povidone iodine
Iodine tincture
Isopropyl myristate
Ketoconazole
Lactic acid
Lanolin
Lidocaine and Pharmaceutical forms intended for
its salts topical application and
administration by injection for
local use only
Loratadine Pharmaceutical form intended for
oral administration
Lorazepam Pharmaceutical form intended for
oral and sublingual administration
in anticipation of surgical
procedures, containing 0.5 mg or
1 mg of Lorazepam per tablet
Quantity limited to 4 tablets
Mafenide and its salts
Menthol
Mepivacaine Pharmaceutical form intended for
administration by injection
for local use only
Methylpolysiloxanes
Methylprednisolone Pharmaceutical forms intended for
acetate topical application and
administration by injection for
local use only
Miconazole nitrate
Mometasone furorate
Mupirocin
Naproxen Pharmaceutical form intended for
oral administration
Quantity limited for 30 days
Neomycin sulfate
Nystatin
Oxiconazole
Phenol
Podophyllin
Polymyxin B sulfate
Pramoxine
Prilocaine Pharmaceutical forms intended for
topical application and
administration by injection for
local use only
Procaine Pharmaceutical form intended for
administration by injection for
local use only
Resorcinol and its salts
Rofecoxib Pharmaceutical form intended for
oral administration
Quantity limited for 30 days
Diethylamine salicylate
Magnesium salicylate
Methyl salicylate
Triethanolamine salicylate
Salicylic acid
Synthetic sebum
Silicone
Sodium thiosulfate
Sulphur, colloidal,
precipitate or sublimate
Tazarotene
Terbinafine
Tetracaine and Pharmaceutical forms intended for
its salts topical application and
administration by injection for
local use only
Tioconazole
Tolnaftate
Triamcinolone Quantity limited for 30 days
acetonide
Triamcinolone Pharmaceutical forms intended for
hexacetonide administration by intramuscular or
intradermal injection
Quantity limited for 30 days
Trichloroacetic acid
Urea Pharmaceutical form intended for
topical application, with a
concentration of 30% or less
White petroleum jelly
Zinc oxide
O.C. 142-2003, s. 3
;
O.C. 522-2005, s. 2
.
REFERENCES
O.C. 1057-91, 1991 G.O. 2, 3231
O.C. 142-2003, 2003 G.O. 2, 1013
O.C. 522-2005, 2005 G.O. 2, 1872
Copy
Select this element
Select parent element
Unselect all
Copy to Drafting
Copy to LAW
Copy to Clipboard
×
To copy : Ctrl+C
0
Contact us
Site map
Québec.ca
Accessibility
Privacy policy
© Gouvernement du Québec
Selections
×
Show
Selections in current document
All selections in the collection
Selected elements
Delete all selections
Show selections
Cyberlex
×
Version 2.2.0.3